Toxicological Profile for Hydrazines. US Department Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Report of the Advisory Group to Recommend Priorities for the IARC Monographs During 2020–2024
IARC Monographs on the Identification of Carcinogenic Hazards to Humans Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024 CONTENTS Introduction ................................................................................................................................... 1 Acetaldehyde (CAS No. 75-07-0) ................................................................................................. 3 Acrolein (CAS No. 107-02-8) ....................................................................................................... 4 Acrylamide (CAS No. 79-06-1) .................................................................................................... 5 Acrylonitrile (CAS No. 107-13-1) ................................................................................................ 6 Aflatoxins (CAS No. 1402-68-2) .................................................................................................. 8 Air pollutants and underlying mechanisms for breast cancer ....................................................... 9 Airborne gram-negative bacterial endotoxins ............................................................................. 10 Alachlor (chloroacetanilide herbicide) (CAS No. 15972-60-8) .................................................. 10 Aluminium (CAS No. 7429-90-5) .............................................................................................. 11 -
Kinetics of Oxidation of Hydrazine & Hydroxylamine by N
Indian Journal of Chemistry VoL I5A, AUQust 1977, pp. 713-715 Kinetics of Oxidation of Hydrazine & Hydroxylamine by N-Chlorobenzamide B. S. RAWAT & M. C. AGRAWAL Department of Chemistry, Harcourt Butler Technological Institute, Kanpur 208002 Received 16 December 1976; accepted 28 February 1977 The rates of oxidation of hydrazine and hydroxylamine by N-chlorobenzamide (NCB) have been measured in hydrochloric acid media. The reactions follow identical kinetics. being first order each in [NCB]. [H+] and [CI-] and show independent nature to the reducing substrates. Added salt and solvent effects are negligible. Molecular chlorine obtained from the reaction of NCB and HCI has been found to be the effective oxidant. XIDATION of hydrazine- and hydroxylamine- excess of NCB at 40°. The results conformed to by a variety of oxidants in aqueous solutions the reactions (1 and 2), O has been studied. In general, hydrazine is N2H4+2C6HsCONHCI = N2+2C6HsCONH2+2HCl quantitatively converted into nitrogen but other ... (1) products such as ammonia and hydrazoic acid have also been reported. 2NH20H+CaHsCONHCI = N2+C6HsCONH2 It was interesting that the oxidation of hydroxyl- +2H20 +HCl ... (2) amine by ferricyanide" showed a variable stoichio- and are in accord with the results of Singh and metry depending upon the relative concentrations coworkers+ who have experimentally obtained nitro- of the reactants. Both hydrazine and hydroxyl- gen and benzamide as the end-products of the amine were quantitatively estimated in strong acidic reaction. solutions by N-chlorobenzamide4• In this paper the results of the kinetics of oxidation of hydrazine Results and hydroxylamine by N-chlorobenzamide (NCB) Effects of varyi1lg [NeB] and [substrates]- are recorded and a suitable mechanism is proposed. -
Monoamine Oxydases Et Athérosclérose : Signalisation Mitogène Et Études in Vivo
UNIVERSITE TOULOUSE III - PAUL SABATIER Sciences THESE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITE TOULOUSE III Discipline : Innovation Pharmacologique Présentée et soutenue par : Christelle Coatrieux le 08 octobre 2007 Monoamine oxydases et athérosclérose : signalisation mitogène et études in vivo Jury Monsieur Luc Rochette Rapporteur Professeur, Université de Bourgogne, Dijon Monsieur Ramaroson Andriantsitohaina Rapporteur Directeur de Recherche, INSERM, Angers Monsieur Philippe Valet Président Professeur, Université Paul Sabatier, Toulouse III Madame Nathalie Augé Examinateur Chargé de Recherche, INSERM Monsieur Angelo Parini Directeur de Thèse Professeur, Université Paul Sabatier, Toulouse III INSERM, U858, équipes 6/10, Institut Louis Bugnard, CHU Rangueil, Toulouse Résumé Les espèces réactives de l’oxygène (EROs) sont impliquées dans l’activation de nombreuses voies de signalisation cellulaires, conduisant à différentes réponses comme la prolifération. Les EROs, à cause du stress oxydant qu’elles génèrent, sont impliquées dans de nombreuses pathologies, notamment l’athérosclérose. Les monoamine oxydases (MAOs) sont deux flavoenzymes responsables de la dégradation des catécholamines et des amines biogènes comme la sérotonine ; elles sont une source importante d’EROs. Il a été montré qu’elles peuvent être impliquées dans la prolifération cellulaire ou l’apoptose du fait du stress oxydant qu’elles génèrent. Ce travail de thèse a montré que la MAO-A, en dégradant son substrat (sérotonine ou tyramine), active une voie de signalisation mitogène particulière : la voie métalloprotéase- 2/sphingolipides (MMP2/sphingolipides), et contribue à la prolifération de cellules musculaire lisses vasculaires induite par ces monoamines. De plus, une étude complémentaire a confirmé l’importance des EROs comme stimulus mitogène (utilisation de peroxyde d’hydrogène exogène), et a décrit plus spécifiquement les étapes en amont de l’activation de MMP2, ainsi que l’activation par la MMP2 de la sphingomyélinase neutre (première enzyme de la cascade des sphingolipides). -
A Guide to Export Controls
Foreign Affairs, Trade and Affaires étrangères, Commerce et Development Canada Développment Canada A Guide To CANADA’S EXPORT CONTROLS December 2012 Introduction The issuance of export permits is administered by the Export Controls Division (TIE) of Foreign Affairs, Trade and Development Canada (DFATD). TIE provides assistance to exporters in determining if export permits are required. It also publishes brochures and Notices to Exporters that are freely available on request and on our website www.exportcontrols.gc.ca. How to contact us: Export Controls Division (TIE) Foreign Affairs, Trade and Development Canada 111 Sussex Drive Ottawa, Ontario K1A 0G2 Telephone: (613) 996-2387 Facsimile: (613) 996-9933 Email: [email protected] For information on how to apply for an export permit and additional information on export controls please refer to our website. To enquire on the status of an export permit application: Recognized EXCOL users can check the status of an export permit application on-line. Non-recognized users can call (613) 996-2387 or email [email protected] and quote your export permit application identification (ref ID) number. Export Controls Division website: www.exportcontrols.gc.ca This Guide, at time of publication, encompasses the list of items enumerated on the Export Control List (ECL) that are controlled for export in accordance with Canadian foreign policy, including Canada’s participation in multilateral export control regimes and bilateral agreements. Unless otherwise specified, the export controls contained in this Guide apply to all destinations except the United States. Canada’s Export Control List can be found at the Department of Justice website at http://canada.justice.gc.ca/. -
California Proposition 65 Toxicity List
STATE OF CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986 CHEMICALS KNOWN TO THE STATE TO CAUSE CANCER OR REPRODUCTIVE TOXICITY 4-Mar-05 The Safe Drinking Water and Toxic Enforcement Act of 1986 requires that the Governor revise and Chemical Type of Toxicity CAS No. Date Listed A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole) cancer 26148685 1-Jan-90 Acetaldehyde cancer 75070 1-Apr-88 Acetamide cancer 60355 1-Jan-90 Acetazolamide developmental 59665 20-Aug-99 Acetochlor cancer 34256821 1-Jan-89 Acetohydroxamic acid developmental 546883 1-Apr-90 2-Acetylaminofluorene cancer 53963 1-Jul-87 Acifluorfen cancer 62476599 1-Jan-90 Acrylamide cancer 79061 1-Jan-90 Acrylonitrile cancer 107131 1-Jul-87 Actinomycin D cancer 50760 1-Oct-89 Actinomycin D developmental 50760 1-Oct-92 Adriamycin (Doxorubicin hydrochloride) cancer 23214928 1-Jul-87 AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide cancer 3688537 1-Jul-87 Aflatoxins cancer --- 1-Jan-88 Alachlor cancer 15972608 1-Jan-89 Alcoholic beverages, when associated with alcohol abuse cancer --- 1-Jul-88 Aldrin cancer 309002 1-Jul-88 All-trans retinoic acid developmental 302794 1-Jan-89 Allyl chloride Delisted October 29, 1999 cancer 107051 1-Jan-90 Alprazolam developmental 28981977 1-Jul-90 Altretamine developmental, male 645056 20-Aug-99 Amantadine hydrochloride developmental 665667 27-Feb-01 Amikacin sulfate developmental 39831555 1-Jul-90 2-Aminoanthraquinone cancer 117793 1-Oct-89 p -Aminoazobenzene cancer -
Transport of Dangerous Goods
ST/SG/AC.10/1/Rev.16 (Vol.I) Recommendations on the TRANSPORT OF DANGEROUS GOODS Model Regulations Volume I Sixteenth revised edition UNITED NATIONS New York and Geneva, 2009 NOTE The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. ST/SG/AC.10/1/Rev.16 (Vol.I) Copyright © United Nations, 2009 All rights reserved. No part of this publication may, for sales purposes, be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying or otherwise, without prior permission in writing from the United Nations. UNITED NATIONS Sales No. E.09.VIII.2 ISBN 978-92-1-139136-7 (complete set of two volumes) ISSN 1014-5753 Volumes I and II not to be sold separately FOREWORD The Recommendations on the Transport of Dangerous Goods are addressed to governments and to the international organizations concerned with safety in the transport of dangerous goods. The first version, prepared by the United Nations Economic and Social Council's Committee of Experts on the Transport of Dangerous Goods, was published in 1956 (ST/ECA/43-E/CN.2/170). In response to developments in technology and the changing needs of users, they have been regularly amended and updated at succeeding sessions of the Committee of Experts pursuant to Resolution 645 G (XXIII) of 26 April 1957 of the Economic and Social Council and subsequent resolutions. -
Of 10 October 2018 Amending Council Regulation (EC) No 428/2009
14.12.2018 EN Official Journal of the European Union L 319/1 II (Non-legislative acts) REGULATIONS COMMISSION DELEGATED REGULATION (EU) 2018/1922 of 10 October 2018 amending Council Regulation (EC) No 428/2009 setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Council Regulation (EC) No 428/2009 of 5 May 2009 setting up a Community regime for the control of exports, transfer, brokering and transit of dual-use items ( 1), and in particular Article 15(3) thereof, Whereas: (1) Regulation (EC) No 428/2009 requires dual-use items to be subject to effective control when they are exported from or transit through the Union, or are delivered to a third country as a result of brokering services provided by a broker resident or established in the Union. (2) Annex I to Regulation (EC) No 428/2009 establishes the common list of dual-use items that are subject to controls in the Union. Decisions on the items subject to controls are taken within the framework of the Australia Group ( 2 ), the Missile Technology Control Regime ( 3 ), the Nuclear Suppliers Group ( 4 ), the Wassenaar Arrangement ( 5 ) and the Chemical Weapons Convention. (3) The list of dual-use items set out in Annex I to Regulation (EC) No 428/2009 needs to be updated regularly so as to ensure full compliance with international security obligations, to guarantee transparency, and to maintain the competitiveness of economic operators. -
Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of -
AHFS Pharmacologic-Therapeutic Classification System
AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective -
Hydrazine Sulfate Hazard Summary Identification
Common Name: HYDRAZINE SULFATE CAS Number: 10034-93-2 RTK Substance number: 2360 DOT Number: None Date: December 1994 Revision: May 2001 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY * Hydrazine Sulfate can affect you when breathed in and * Exposure to hazardous substances should be routinely may be absorbed through the skin. evaluated. This may include collecting personal and area * Hydrazine Sulfate should be handled as a air samples. You can obtain copies of sampling results CARCINOGEN—WITH EXTREME CAUTION. from your employer. You have a legal right to this * Hydrazine Sulfate can irritate and burn the eyes and skin. information under OSHA 1910.1020. * Breathing Hydrazine Sulfate can irritate the nose, throat * If you think you are experiencing any work-related health and lungs causing coughing and shortness of breath. problems, see a doctor trained to recognize occupational * Exposure can cause you to feel dizzy and lightheaded. diseases. Take this Fact Sheet with you. Higher levels can cause trembling, a feeling of excitement, and even convulsions (fits). WORKPLACE EXPOSURE LIMITS * Hydrazine Sulfate may damage blood cells causing a low No occupational exposure limits have been established for blood count (anemia). Hydrazine Sulfate. This does not mean that this substance is * Exposure may damage the liver and kidneys. not harmful. Safe work practices should always be followed. * Hydrazine Sulfate may cause a skin allergy. If allergy develops, very low future exposure can cause itching and a * Hydrazine Sulfate may be a CARCINOGEN in humans. skin rash. There may be no safe level of exposure to a carcinogen, so all contact should be reduced to the lowest possible level. -
The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
CORE Metadata, citation and similar papers at core.ac.uk Provided by Archivio della ricerca- Università di Roma La Sapienza Send Orders for Reprints to [email protected] 6 Current Vascular Pharmacology, 2015, 13, 6-19 The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair Emanuela Turillazzi1*, Cristoforo Pomara1, Stefania Bello1, Margherita Neri1, Irene Riezzo1 and Vittorio Fineschi2 1Institute of Legal Medicine, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy; 2Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza Uni- versity of Rome, Rome, Italy Abstract: Although a decline in the all-cause and cardiac mortality rates following myocardial infarction (MI) during the past 3 decades has been reported, MI is a major cause of death and disability worldwide. From a pathological point of view MI consists in a particular myocardial cell death due to prolonged ischemia. After the onset of myocardial ischemia, cell death is not immediate, but takes a finite period of time to develop. Once complete myocytes’ necrosis has occurred, a process leading to a healed infarction takes place. In fact, MI is a dynamic proc- ess that begins with the transition from reversible to irreversible ischemic injury and culminates in the replacement of dead myocardium by a fibrous scar. The pathobiological mechanisms underlying this process are very complex, involving an in- flammatory response by several pathways, and pose a major challenge to ability to improve our knowledge. An improved un- derstanding of the pathobiology of cardiac repair after MI and further studies of its underlying mechanisms provide avenues for the development of future strategies directed toward the identification of novel therapies. -
Alar Five Years Later
Alar Five Years Later by Kenneth Smith This special report was written for the American Council on Science and Health by Kenneth Smith, Editorial Writer of The Washington Times as a follow-up to the two previous reports: Alar One Year Later andAlar Three Years Later. ACSH gratefully acknowledges the comments and contributions of the following individuals who reviewed one or more editions of this report: F. J. Francis, Ph.D. University of Massachusetts Lois S. Gold, Ph.D. University of California, Berkeley Thomas H. Jukes, Ph.D. University of California, Berkeley Roger P. Maickel, Ph.D. Purdue University A. Alan Moghissi, Ph.D. Temple University Robert E. Olson, M.D., Ph.D. SUNY at Stony Brook Thomas W. Orme, Ph.D. American Council on Science and Health Edward G. Remmers, Sc.D. American Council on Science and Health Joseph Rosen, Ph.D. Rutgers University Fredrick J. Stare, M.D., Ph.D. Harvard School of Public Health Elizabeth M. Whelan, Sc.D., M.P.H. American Council on Science and Health “As a pediatric surgeon, as well as the nation’s former surgeon general, I care deeply about the health of children — and if Alar ever posed a health hazard, I would have said so then and would say so now. When used in the regulated, approved manner as Alar was before it was with- drawn in 1989, Alar-treated apple products posed no hazard to the health of children or adults.” — C. Everett Koop, M.D. Executive Summary In early 1989, this country suffered the public relations equivalent of a natural disaster, one that most scientists now believe should never have occurred.